Survival outcome of women with synchronous cancers of endometrium and ovary: a 10 year retrospective cohort study

Yong Kuei Lim,Rama Padma,Lilian Foo,Yin Nin Chia,Philip Yam,John Chia,HS Khoo-Tan,Swee Peng Yap,Richard Yeo 대한부인종양학회 2011 Journal of Gynecologic Oncology Vol.22 No.4

Objective: Synchronous occurrence of endometrial and ovarian tumors is uncommon, and they affect less than 10% of women with endometrial or ovarian cancers. The aim of this study is to describe the epidemiological and clinical factors; and survival outcomes of women with these cancers. Methods: This is a retrospective cohort study in a large tertiary institution in Singapore. The sample consists of women with endometrial and epithelial ovarian cancers followed up over a period of 10 years from 2000 to 2009. The epidemiological and clinical factors include age at diagnosis, histology types, grade and stage of disease. Results: A total of 75 patients with synchronous ovarian and endometrial cancers were identified. However, only 46 patients met the inclusion criteria. The median follow-up was 74 months. The incidence rate for synchronous cancer is 8.7% of all epithelial ovarian cancers and 4.9% of all endometrial cancers diagnosed over this time frame. Mean age at diagnosis was 47.3 years old. The most common presenting symptom was abnormal uterine bleeding (36.9%) and 73.9% had endometrioid histology for both endometrial and ovarian cancers. The majority of the women (78%) presented were at early stages of 1 and 2. There were 6 (13.6%) cases of recurrence and the 5 year cumulative survival rate was at 84%. Conclusion: In our cohort, we found that majority of women afflicted with synchronous cancer of the endometrium and ovary were younger at age of diagnosis, had early stage of cancer and good survival. Objective: Synchronous occurrence of endometrial and ovarian tumors is uncommon, and they affect less than 10% of women with endometrial or ovarian cancers. The aim of this study is to describe the epidemiological and clinical factors; and survival outcomes of women with these cancers. Methods: This is a retrospective cohort study in a large tertiary institution in Singapore. The sample consists of women with endometrial and epithelial ovarian cancers followed up over a period of 10 years from 2000 to 2009. The epidemiological and clinical factors include age at diagnosis, histology types, grade and stage of disease. Results: A total of 75 patients with synchronous ovarian and endometrial cancers were identified. However, only 46 patients met the inclusion criteria. The median follow-up was 74 months. The incidence rate for synchronous cancer is 8.7% of all epithelial ovarian cancers and 4.9% of all endometrial cancers diagnosed over this time frame. Mean age at diagnosis was 47.3 years old. The most common presenting symptom was abnormal uterine bleeding (36.9%) and 73.9% had endometrioid histology for both endometrial and ovarian cancers. The majority of the women (78%) presented were at early stages of 1 and 2. There were 6 (13.6%) cases of recurrence and the 5 year cumulative survival rate was at 84%. Conclusion: In our cohort, we found that majority of women afflicted with synchronous cancer of the endometrium and ovary were younger at age of diagnosis, had early stage of cancer and good survival.

FIGO staging of endometrial cancer: 2023

Jonathan S. Berek,Xavier Matias-Guiu,Carien Creutzberg,Christina Fotopoulou,David Gaffney,Sean Kehoe,Kristina Lindemann,David Mutch,Nicole Concin,Endometrial Cancer Staging Subcommittee,FIGO Women's C 대한부인종양학회 2023 Journal of Gynecologic Oncology Vol.34 No.5

Introduction: Many advances in the understanding of the pathologic and molecular features of endometrial cancer have occurred since the FIGO staging was last updated in 2009. Substantially more outcome and biological behavior data are now available regarding the several histological types. Molecular and genetic findings have accelerated since the publication of The Cancer Genome Atlas (TCGA) data and provide improved clarity on the diverse biological nature of this collection of endometrial cancers and their differing prognostic outcomes. The goals of the new staging system are to better define these prognostic groups and create substages that indicate more appropriate surgical, radiation, and systemic therapies. Methods: The FIGO Women's Cancer Committee appointed a Subcommittee on Endometrial Cancer Staging in October 2021, represented by the authors. Since then, the committee members have met frequently and reviewed new and established evidence on the treatment, prognosis, and survival of endometrial cancer. Based on these data, opportunities for improvements in the categorization and stratification of these factors were identified in each of the four stages. Data and analyses from the molecular and histological classifications performed and published in the recently developed ESGO/ESTRO/ESP guidelines were used as a template for adding the new subclassifications to the proposed molecular and histological staging system. Results: Based on the existing evidence, the substages were defined as follows: S tage I (IA1): non-aggressive histological type of endometrial carcinoma limited to a polyp or confined to the endometrium; (IA2) non-aggressive histological types of endometrium involving less than 50% of the myometrium with no or focal lymphovascular space invasion (LVSI) as defined by WHO criteria; (IA3) low-grade endometrioid carcinomas limited to the uterus with simultaneous low-grade endometrioid ovarian involvement; (IB) non-aggressive histological types involving 50% or more of the myometrium with no LVSI or focal LVSI; (IC) aggressive histological types, i.e. serous, high-grade endometrioid, clear cell, carcinosarcomas, undifferentiated, mixed, and other unusual types without any myometrial invasion. S tage II (IIA): non-aggressive histological types that infiltrate the cervical stroma; (IIB) non-aggressive histological types that have substantial LVSI; or (IIC) aggressive histological types with any myometrial invasion. S tage III (IIIA): differentiating between adnexal versus uterine serosa infiltration; (IIIB) infiltration of vagina/parametria and pelvic peritoneal metastasis; and (IIIC) refinements for lymph node metastasis to pelvic and para-aortic lymph nodes, including micrometastasis and macrometastasis. S tage IV (IVA): locally advanced disease infiltrating the bladder or rectal mucosa; (IVB) extrapelvic peritoneal metastasis; and (IVC) distant metastasis. The performance of complete molecular classification (POLEmut, MMRd, NSMP, p53abn) is encouraged in all endometrial cancers. If the molecular subtype is known, this is recorded in the FIGO stage by the addition of “m” for molecular classification, and a subscript indicating the specific molecular subtype. When molecular classification reveals p53abn or POLEmut status in Stages I and II, this results in upstaging or downstaging of the disease (IICmp53abn or IAmPOLEmut). Summary: The updated 2023 staging of endometrial cancer includes the various histological types, tumor patterns, and molecular classification to better reflect the improved understanding of the complex nature of the several types of endometrial carcinoma and their underlying biologic behavior. The changes incorporated in the 2023 staging system should provide a more evidence-based context for treatment recommendations and for the more refined future collection of outcome and survival data.

Risk Factors Associated with Endometrial Pathology in Premenopausal Breast Cancer Patients Treated with Tamoxifen

이마리아,Jinlan Piao,전명재 연세대학교의과대학 2020 Yonsei medical journal Vol.61 No.4

Purpose: To evaluate factors associated with endometrial pathology during tamoxifen use in premenopausal breast cancer (BC) patients. Materials and Methods: We reviewed the medical records of premenopausal BC patients treated with tamoxifen who underwent endometrial biopsy with or without hysteroscopy. Clinical characteristics were compared between women with endometrial pathology (endometrial hyperplasia or cancer) and those with normal histology or endometrial polyps. Results: Among 284 endometrial biopsies, endometrial hyperplasia was diagnosed in 7 patients (2.5%), endometrial cancer was diagnosed in 5 patients (1.8%), normal histology was noted in 146 patients (51.4%), and endometrial polyp was present in 114 patients (40.1%). When comparing women with endometrial cancer (n=5) to women with normal histology, abnormal uterine bleeding was more common (p=0.007), and endometrial thickness was greater (p=0.007) in women with endometrial cancer. Chemotherapy for BC was also more common in patients with endometrial cancer (p=0.037). When comparing women with endometrial polyps and those with endometrial hyperplasia or cancer, the presence of abnormal uterine bleeding was more common in patients with endometrial hyperplasia or cancer (p<0.001); however, tamoxifen duration and endometrial thickness did not differ significantly between the two groups. Conclusion: In premenopausal BC patients treated with tamoxifen, abnormal uterine bleeding, increased endometrial thickness, and chemotherapy for BC were associated with the occurrence of endometrial cancer. These findings may provide useful information for gynecologic surveillance and counseling during tamoxifen treatment in premenopausal BC patients.

Steroid hormone intervenes in the endometrial tumorigenesis of Pten ablation

김홍임,김태훈,임정묵,정재욱 대한암예방학회 2013 Journal of cancer prevention Vol.18 No.4

Endometrial cancer, the most common gynecological cancer, is closely associated with endometrial hyperplasia, unopposed estrogen exposure, and genetic alterations. Phosphatase and tensin homologue (PTEN) is a tumor suppressor genes completely lost or mutated in >50% of primary endometrioid endometrial cancers. Estrogen-dependent endometrioid carcinoma is the most common type of endometrial cancer. Progesterone is a hormone that antagonizes the growth-promoting properties of estrogen in the uterus. Progestin is used as a conservative endocrine treatment of early endometrial cancer in order to preserve fertility as well as a palliative measure for advanced-stage patients. Progesterone therapy has been shown to be effective in preventing endometrial cancer as well as controlling growth of the endometrium. However, the effectiveness of progestin for women with endometrial cancer is less clear. In order to understand the effect of steroid hormone on endometrial cancer progression, we used a mouse endometrial cancer model with conditional loss of Pten in the mouse uterus (PRcre/+Ptenf/f, Ptend/d). To assess the effect of steroid hormones, ovariectomized Ptenf/f and Ptend/d mice were treated with estrogen or progesterone over a period of three month. Uterine weight gain was significantly decreased in ovariectomized PRcre/+Ptenf/f mice compared to intact PRcre/+Ptenf/fmice. Ovariectomized PRcre/+Ptenf/fmice treated with P4 or vehicle also exhibited decreased uterine cancer size compared with intact PRcre/+Ptenf/f mice. Proliferation of ovariectomized PRcre/+Ptenf/fmice treated with P4 is highly decreased compared to other groups. The levels of stromal progesterone receptor were highly increased in ovariectomized PRcre/+Ptenf/fmice treated with P4 which resulted in decreased epithelial proliferation. Therefore, these results suggest that P4 treatment significantly reduces tumor mass but does not affect cancer progression in PRcre/+Ptenf/fmice.

Are Neutrophil/Lymphocyte and Platelet/Lymphocyte Ratios Associated with Endometrial Precancerous and Cancerous Lesions in Patients with Abnormal Uterine Bleeding?

Acmaz, Gokhan,Aksoy, Huseyin,Unal, Dilek,Ozyurt, Sezin,Cingillioglu, Basak,Aksoy, Ulku,Muderris, Ipek Asian Pacific Journal of Cancer Prevention 2014 Asian Pacific journal of cancer prevention Vol.15 No.4

Background: An easy, reproducible and simple marker is needed to estimate phase of endometrial pathologic lesions such as hyperplasia and endometrial cancer and distinguish from pathologically normal results. We here aimed to clarify associations among neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), endometrial hyperplasia and cancer in patients with abnormal uterine bleeding. Materials and Methods: Patients (n=161) who were admitted with abnormal uterine bleeding and the presence of endometrial cells on cervical cytology or thick endometrium were investigated. The study constituted of three groups according to pathologic diagnosis. Group 1 included endometrial precancerous lesions like hyperplasia (n=63), group 2 included endometrial cancerous lesions (n=38) and group 3 was a pathologically normal group (n=60). Blood samples were obtained just before the curettage procedure and the NLR was defined as the absolute neutrophil count divided by the absolute lymphocyte count; similarly, PLR was defined as the absolute platelet count divided by the absolute lymphocyte count. Results: The white blood cell count was significantly higher in patients with cancer than in those with hyperplasia (p=0.005). The platelet count and neutrophil to lymphocyte ratio were significantly higher in patients with cancer than in control patients, but there was significantly no difference between patients with hyperplasia and other groups (p=0.001 and p=0.025 respectively). PLR was significantly lower in control subjects than in other groups (p<0.001), but there was no significant difference between patients with hyperplasia and those with cancer. Conclusions: PLR was significantly lower in control subjects than in other groups. Thus both hyperplasia and cancer may be differentiated from pathologically normal patients by using PLR. White blood cell count was significantly higher in patients with cancer than in those with hyperplasia and pathologically normal patients. Therefore white blood cell count may be used for discriminate hyperplasia to cancer. By using multiple inflammation parameters, discrimination may be possible among endometrial cancer, endometrial precancerous lesions and pathologically normal patients.

Sequential chemotherapy and radiotherapy as sandwich therapy for the treatment of high risk endometrial cancer

Lisa N. Abaid,Mark A. Rettenmaier,John V. Brown III,John P. Micha,Alberto A. Mendivil,Marie A. Wabe,Bram H. Goldstein 대한부인종양학회 2012 Journal of Gynecologic Oncology Vol.23 No.1

Objective: The purpose of this retrospective study was to assess the tolerability and efficacy of sequential chemotherapy and radiotherapy for the treatment of high risk endometrial cancer. Methods: We conducted a retrospective study of previously untreated high risk endometrial cancer patients who received sequential chemotherapy and radiotherapy in accordance with the sandwich approach from June 2008 until June 2011. High risk endometrial cancer patients underwent complete surgical staging followed by adjuvant therapy encompassing sequential chemotherapy, radiation therapy and consolidation chemotherapy. Results: The study analysis comprised 32 endometrial cancer patients. All subjects were treated with carboplatin and paclitaxel chemotherapy; currently, 186 cycles have been administered and 94% of patients have completed the planned number of cycles. Grade 3 neutropenia developed in 1 (3.1%) patient; there was no incidence of grade 4 neutropenia. Moreover, we observed grade 3 anemia in four (12.5%) patients and grade 4 anemia in one (3.1%) patient. One (3.1%) patient developed grade 3 thrombocytopenia; grade 4 thrombocytopenia was not observed. Five patients exhibited progressive disease, three of whom have since expired; mean progression free survival and follow-up were 17.4 months and 18.9 months, respectively. Conclusion: The preliminary results from our study suggest that the sandwich approach to treating high risk endometrial cancer patients is feasible. Hematologic toxicity was well tolerated and non-hematologic toxicity was mild and easily managed. Further study of this novel regimen in a larger patient population with extended follow-up is necessary. Objective: The purpose of this retrospective study was to assess the tolerability and efficacy of sequential chemotherapy and radiotherapy for the treatment of high risk endometrial cancer. Methods: We conducted a retrospective study of previously untreated high risk endometrial cancer patients who received sequential chemotherapy and radiotherapy in accordance with the sandwich approach from June 2008 until June 2011. High risk endometrial cancer patients underwent complete surgical staging followed by adjuvant therapy encompassing sequential chemotherapy, radiation therapy and consolidation chemotherapy. Results: The study analysis comprised 32 endometrial cancer patients. All subjects were treated with carboplatin and paclitaxel chemotherapy; currently, 186 cycles have been administered and 94% of patients have completed the planned number of cycles. Grade 3 neutropenia developed in 1 (3.1%) patient; there was no incidence of grade 4 neutropenia. Moreover, we observed grade 3 anemia in four (12.5%) patients and grade 4 anemia in one (3.1%) patient. One (3.1%) patient developed grade 3 thrombocytopenia; grade 4 thrombocytopenia was not observed. Five patients exhibited progressive disease, three of whom have since expired; mean progression free survival and follow-up were 17.4 months and 18.9 months, respectively. Conclusion: The preliminary results from our study suggest that the sandwich approach to treating high risk endometrial cancer patients is feasible. Hematologic toxicity was well tolerated and non-hematologic toxicity was mild and easily managed. Further study of this novel regimen in a larger patient population with extended follow-up is necessary.

Relations of Platelet Indices with Endometrial Hyperplasia and Endometrial Cancer

Karateke, Atilla,Kaplanoglu, Mustafa,Baloglu, Ali Asian Pacific Journal of Cancer Prevention 2015 Asian Pacific journal of cancer prevention Vol.16 No.12

Background: Platelets are blood elements thought to play a role in the immune system and therefore tumor development and metastasis. Platelet activation parameters such as mean platelet volume (MPV), platelet distribution width (PDW), and plateletcrit (PCT) can be easily evaluated with the whole blood count and have been studied as markers of systemic inflammatory responses in various cancer types. Our aim in this study was to evaluate the correlation between endometrial pathologies and MPV, PDW and PCT. Materials and Methods: A total of 194 patients who presented to our clinic with abnormal vaginal bleeding were included in our study. The patients were divided into 3 groups (endometrial hyperplasia, endometrial cancer, control) according to their pathology results. The groups were compared for MPV, PDW, and PCT values obtained from the blood samples taken on endometrial biopsy day. Results: The endometrial cancer patients were the oldest group (p=0.04). There was no significant difference between the three groups in terms of white blood cell count (WBC), platelet count (PC), and hemoglobin (Hb) level. The highest MPV (p<0.001), PDW (p=0.002), and PCT (p<0.001) levels were in the endometrial cancer group, and the lowest levels were in the control group. Conclusions: The easy evaluation of platelet parameters in patients who are suspected of having endometrial pathology is a significant advantage. We found MPV, PDW, and PCT to be correlated with the severity of endometrial pathology with the highest values in endometrial cancer. Studies to be conducted together with different laboratory parameters will further help evaluate the diagnosis and severity of endometrial cancer and precursor lesions.

The Significance of miR-34a Expression in Endometrial Carcinogenesis: Correlation With Expression of p16 and Ki-67 Proteins in Endometrial Cancers

Yoon Sung Choi,Kyung Eun Lee 대한암예방학회 2015 Journal of cancer prevention Vol.20 No.4

Background: A microRNA, miR-34a, plays a key role in inhibiting cellular transformation and carcinogenesis by controlling cell cycle regulation and cell proliferation in various human tumors. However, miR-34a has rarely been reported in endometrial cancer research in Korea. This study was undertaken to analyze miR-34a expression in simple endometrial hyperplasia and endometrial cancer, and to evaluate the relationship between expression of miR-34a and p16 and Ki-67 proteins in endometrial cancers. Methods: A retrospective study was carried out on 66 formalin-fixed, paraffin-embedded tissues with simple endometrial hyperplasia (31 cases) and endometrial cancer (35 cases) patients. These were analyzed for miR-34a expression by quantitative real-time PCR , and the expression of p16 and Ki-67 proteins in endometrial cancers was evaluated by immunohistochemistry. Results: The miR-34a expression level was lower in endometrial cancer tissues (−0.71 ± 3.90) than in simple endometrial hyperplasia tissues (2.68 ± 8.62). The endometrial hyperplasia tissues showed underexpression of miR-34a in 13 of the 31 cases (41.9%) while the endometrial cancer tissues showed underexpression of miR-34a in 24 of 35 cases (68.6%). Thus, miR-34a was significantly underexpressed in endometrial cancer tissues when compared endometrial hyperplasia tissues (P = 0.046). Overexpression of p16 was detected in 25 (71.4%) and Ki-67 immunoreactivity was detected in 27 (77.1%) of the 35 endometrial cancers. Although not statistically significant, the frequency of p16 and Ki-67 overexpression tended to be lower in the cases with miR-34a underexpression than in cases with miR-34a overexpression. Conclusions: These findings suggest that underexpression of miR-34a might be involved in endometrial carcinogenesis. Further studies are needed to define the relationship between miR-34a expression and tissue specific protein expression.

자궁내막암, 자궁내막증식증, 정상자궁내막에 있어서 CD44 Variant 6 (V6)의 발현

송재윤 ( Jae Yun Song ),박현태 ( Hyun Tae Park ),이낙우 ( Nack Woo Lee ),김영태 ( Young Tae Kim ),김인선 ( In Sun Kim ),이규완 ( Kyu Wan Lee ) 대한산부인과학회 2002 Obstetrics & Gynecology Science Vol.45 No.9

목적 : 정상 자궁내막과, 자궁내막증식증 (endometrial hyperplasia), 그리고 자궁내막암 (endometrial cancer)에 있어서 CD44 V6의 표현의 차이와 CD44 V6의 자궁내막암의 예후예측인자로서의 여부에 대하여 알아보고자 한다. 연구 방법 : 1991년부터 2001년까지 본원에서 진단된 총 76명의 환자를 대상으로 자궁내막증식증 (endometrial hyperplasia) 15예, 자궁내막암 24예 그리고 정상내막 37예를 대상으로 하였으며 면역양성반응과 면역강도를 종합하여 면역활성도 (immunoreactivity)를 평가하였다. 결과 : 정상조직이나 자궁내막증식증에 비해서 자궁내막암의 경우 통계학적으로 유의한 양성 소견을 나타내었다. (P<0.05) 면역활성도를 자궁근층의 침범이 나타나기 이전의 Ia와 침범이 나타나는 Ib 이상으로 나누어 보면 통계학적 유의성을 나타내지는 못하였다. 조직분화도에 따른 면역활성도는 grade 1에서 유의한 증가를 나타내었다. 결론 : CD44 V6의 표현은 자궁내막암의 조기진단에 이용될 수 있으며 자궁내막암의 예후예측인자로서도 이용될 수 있으리라 사료된다. Objective : To compare the expression of CD44 V6 in normal endometrium, endometrial hyperplasia, and endometrial cancer and to evaluate CD44 variant 6 for prognostic marker. Methods : Seventy six endometrial samples at Korea University Anam Hospital from 1991 to 2001 (37normal endometirum, 15 endometrial hyperplasia, and 24 endometrial cancer ) were immunohistochemically investigated for the expression of variant 6, isoform of CD44. Immunoreactivity scores were generated by multiplication of the values for the immunopositivity and immunointensity. Results : CD44 V6 was detected in 19/37 cases of normal endometrium (only secretory phase), 1/15 endometrial hyperplasia, and 24/24 endometrial cancer. Immunoreactivity was higher in well differentiated endometrial cancer, while no association was noted with cancer stage. Conclusion : CD44 V6 expression in normal endometrium is observed in the secretory phase. Detection of expression of CD44 V6 may be useful for the early diagnosis of endometrial cancer and may be an useful prognostic marker.

자궁내막암에서 Angiopoietin-1 & -2 및 Tie-2 mRNA의 발현에 관한 연구

이경아 ( Kyung A Lee ),김아리 ( A Ri Kim ),강은지 ( Eun Ji Kang ),문혜성 ( Hye Sung Moon ),정혜원 ( Hye Won Chung ),김승철 ( Seung Cheol Kim ),김종일 ( Jong Il Kim ) 대한산부인과학회 2006 Obstetrics & Gynecology Science Vol.49 No.9

목적: 본 연구에서는 자궁내막암과 자궁내막증식증 및 정상 자궁내막조직에서의 Angiopoietin-1 & -2 및 Tie-2 mRNA 발현을 연구함으로서, 자궁내막암의 암화과정에 관여하는지를 알아보고자 하였으며 Angiopoietin-1 & -2 및 Tie-2 mRNA 발현의 차이를 알아보고 자궁내막암 예후인자와의 관련성을 알아보고자 하였다. 연구 방법: 20예의 자궁내막암 환자와 10예의 자궁내막증식증 환자와 24예의 정상 자궁내막 조직에서 RT-PCR과 QC-PCR을 이용하여 Angiopoietin-1 & -2 및 Tie-2 mRNA 발현을 비교하였다. 결과: 자궁내막암과 자궁내막증식증 및 정상 자궁내막 조직에서 Angiopoietin-1 & -2 및 Tie-2 mRNA가 발현되었으며 자궁내막암에서 Angiopoietin-1 & -2 mRNA가 정상 자궁내막조직보다는 통계적으로 유의하게 낮게 발현되었고 자궁내막증식증보다는 통계적으로 유의하게 높게 발현되었다 (p<0.05). 자궁내막암에서 Ang-1 mRNA의 발현은 각 병기와 CA-125 level에 따라 통계적으로 유의한 차이를 보였으며 (p<0.05), Ang-2 mRNA와 Tie-2 mRNA의 임상적 예후인자와 통계적으로 유의한 차이를 보이지 않았다 (p>0.05). Ang-1와 Ang-2 mRNA 발현 간에는 유의한 상관관계가 있었다 (p<0.05). 결론: Angiopoietin-1 & -2 및 Tie-2는 자궁내막암의 진행 및 전이와 관련이 있으며, 특히 Angiopoietin-1 mRNA 발현은 예후인자와 상관관계가 있고, Ang-1과 Ang-2 mRNA 상호 발현이 통계적으로 유의한 관련성이 있으므로 이들의 예후인자로서의 가능성을 생각해 볼 수 있었다. Objective: This study was purposed to investigate the expression of angiopoietin (Ang) -1 & -2 and Tie-2 mRNA among uterine endometrial cancer, endometrial hyperplasia, and normal endometrium, and to assess the relationships among their expression and other prognostic factors of uterine endometrial cancer. Methods: The tissues were obtained from patients with uterine endometrial cancer, patients with endometrial hyperplasia, and patients with normal endometrium undergoing hysterectomy. Total RNA was extracted and reverse transcribed into cDNA. Reverse transcription polymerase chain reaction (RT-PCR) and quantitative competitive-PCR (QC-PCR) were performed to evaluate the mRNA expressions of Ang-1 & -2 and Tie-2. Clinicopathologic factors of uterine endometrial cancer were reviewed with the patient`s charts and results were analyzed with Mann-Whitney U test, Spearman correlation test and logistic regression analysis. Results: Ang-1 & -2 mRNA expression in uetrine endometrial cancer were higher than that in endometrial hyperplasia and lower than that in normal endometrium (p<0.05), but there was no significant difference in Tie-2 mRNA expression among uterine endometrial cancer, endometrial hyperplasia, and normal endometrium. A definite correlation was found between Ang-1 mRNA expression and clinical stage and CA-125 levels of uterine endometrial cancer (p<0.05). Conclusion: The expression of Ang-1 & -2 mRNA could be associated with the progression of uterine endometrial cancer and might have a role as prognostic parameters in uterine endometrial cancer.